Sun S.S.Liu F.Y.Tsai J.J.P.RUOH-FANG YENKao C.H.Huang W.S.2020-09-232020-09-2320030172-8172https://scholars.lib.ntu.edu.tw/handle/123456789/514534Technetium-99m hexamethylpropylene amine oxime (99mTc HMPAO) brain single photon emission computed tomography (SPECT) was used to evaluate the effects of anticoagulant therapy (ACT) on regional cerebral blood flow (rCBF) in patients with primary antiphospholipid antibody syndrome (PAPS). Sixteen female PAPS patients with neuropsychiatric manifestations and hypoperfusion lesions demonstrated on initial 99mTc HMPAO brain SPECT images were enrolled in this study. Follow-up 99mTc HMPAO brain SPECT images were performed 1 month after ACT. Meanwhile, serum anticardiolipin antibodies (ACA) were measured before and after ACT. Before ACT, 14 (87.5%) patients had positive ACA. After ACT, all 16 PAPS patients showed decreased serologic findings, and their neuropsychiatric manifestations subsided. After ACT, 11 (68.8%) patients showed complete recovery of regional cerebral blood flow (rCBF) and five (31.2%) patients showed partial recovery in the follow-up 99mTc HMPAO brain SPECT images. This type of imaging is a logical and objective tool for measuring the effects of ACT in PAPS patients with brain involvement by determining changes in rCBF.[SDGs]SDG3acetylsalicylic acid; anticoagulant agent; cardiolipin antibody; hexamethylpropylene amine oxime technetium tc 99m; phospholipid antibody; warfarin; anticoagulant agent; diagnostic agent; radiopharmaceutical agent; warfarin; adult; antibody blood level; antiphospholipid syndrome; article; brain blood flow; brain disease; brain perfusion; clinical article; convalescence; diagnostic imaging; drug effect; female; follow up; human; neuropsychiatry; priority journal; single photon emission computer tomography; thrombosis; antiphospholipid syndrome; brain; brain circulation; clinical trial; cognitive defect; middle aged; pathophysiology; physiology; scintiscanning; treatment outcome; vascularization; Adult; Anticoagulants; Antiphospholipid Syndrome; Brain; Cerebrovascular Circulation; Delirium, Dementia, Amnestic, Cognitive Disorders; Female; Humans; Middle Aged; Radiopharmaceuticals; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Warfarinjournal article10.1007/s00296-003-0314-3126848372-s2.0-0344254764